Join us 11/05/25 @ 1pm EST for the Spotlight on Evidence Synthesis Program talk featuring Drs. K. Goldstein, P. Klimek-Johnson & J. Vick on their latest work. @VAResearch @DurhamADAPT @SFVAMC @YaleMed Register Here: https://t.co/GAiqjOORaf Must have a @va.gov email to register.

NEW! The ACR just released an updated clinical practice guideline for #SLE! Key recommendations include universal hydroxychloroquine use, lower steroid exposure, & earlier immunosuppressive therapy. Patient-centered care is central. READ MORE → https://t.co/wRUuS5p2HG

New this (half) week in AC&R Impact of digital health app using acceptance & commitment therapy on axSpA outcomes https://t.co/jwsXLDtbnX Personalized approach to managing chronic low back pain in older veterans https://t.co/iDrkoUqweo Polypharmacy in adults with SLE

Cross-sectional study of adults with SLE in the US estimated 56.3% had polypharmacy (≥5 prescription or OTC meds). In addition to immunomodulating drugs, other meds driving polypharmacy included anti-hypertensives (61.9%), non-opioid pain relievers (51.7%), allergy treatments

Experts will discuss machine learning in rheumatology during a Tuesday session at #ACR25. 🔗 Learn more in ACR Convergence Today → https://t.co/CP4smOtI28

⭐ #ACR25 poster spotlight: @SydneyLiles99 shares insight into the poster Does Physical Activity Differ Among Those with Autoimmune vs Non-Autoimmune Rheumatic Diseases? 🔗 Learn more → https://t.co/9Hwmujtsoy

We're excited to announce Kelli Allen & Daniel White have been selected as co-editors-in-chief of Arthritis Care & Research! 👏 We look forward to Drs. Allen & White's new tenure in 2026 to further AC&R's mission of publishing innovative & impactful research in rheumatology care

Journals of the ACR: More Than Just an Impact Factor! ❇️ Arthritis & Rheumatology ❇️ Arthritis Care & Research ❇️ ACR Open Rheumatology ℹ️ Learn more about the journals at the #ACR25 ACR Hub: Exhibit Hall F2

Packed week of papers in Arthritis Care & Research! Discordance in disease activity metrics modestly assoc. w/ worse nociplastic pain https://t.co/bhzKrb0HL9 Meta-analysis of algorithms to identify RA & JIA in EHRs https://t.co/2Oxm32mRyy Financial distress in people w/ RA

Development of a composite social factor index showed assoc. between social disadvantage & SpA pain severity, such that unemployed individuals, those living in inadequate housing, and patients from lower social classes had higher predicted pain AC&R https://t.co/1OQncsdPUi

Come out and talk with us about the ACR journals!

New in Arthritis Care & Research Racial differences in low back pain incidence & prevalence, 1973-2025, across chronicity states https://t.co/8XjfA3MSUi Early TNFi initiation not associated with reduced risk of chronic opioid use in axSpA patients https://t.co/MPN3zkuu0H High

Big TY to our 18u(’26) for their hard work & dedication over the yrs. This class was our very 1st 10u team that have finished their tenure at Riptide going 25-5-1 in ‘25 & leaving our program as hard working individuals. We are very excited for their senior yr & beyond.

New in Arthritis Care & Research → Developing a prediction model to identify patients at risk of difficult-to-treat RA https://t.co/X9YXpnFr34 Opioid prescribing trends for adults with axSpA https://t.co/zGciS9uVA8 Review: Current Raynaud phenomenon treatment guidelines that

Study identified a panel of serum soluble mediators as potential biomarkers for monitoring proliferative lupus nephritis. Early reductions in syndecan-1 and VCAM-1 were predictive of 12-month treatment response in proliferative LN AC&R https://t.co/ssCub8wOeX

Arthritis Care & Research - October Issue Editor's Pick 👉 Metabolic Consequences of Rheumatoid Arthritis https://t.co/QhJPh7wlAQ Review examines current understanding of mechanisms underlying disruptions in metabolic pathways in RA, their clinical effects, & how treatment

Day 41 - 10/4/25 Thankful for the opportunity to compete today at the @scotsbaseball staff and thank you to the coaches for hosting a great event. 2K's in 2IN and 1R, all pitches firing and hitting spots. #uncommitted @M_Luszczynski @travlindy

Treatment of pain related to Raynaud phenomenon is a challenge due to diagnostic and training limitations and therapeutic access to guideline-based vasodilator medications. Review in AC&R examines current RP treatment guidelines that focus on vasodilation https://t.co/iAk1WBBkgJ

Honored to work on this trial with a great team at @DurhamADAPT and great partners in the VA. @FederalPT @UNCTARC @VAResearch

New in Arthritis Care & Research → IBD patient claims data 2000-2022 for NSAID & opioid prescription and MSK pain codes https://t.co/XDa0Uo5nYe Suboptimal proportion of SLE patients attaining LLDAS and DORIS-remission under usual care https://t.co/0q6MfuoXAr Impact of